Current Report Filing (8-k)
April 12 2021 - 6:56AM
Edgar (US Regulatory)
0000025743
false
0000025743
2021-04-08
2021-04-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 8, 2021
TherapeuticsMD, Inc.
(Exact Name of Registrant as Specified in
Its Charter)
Nevada
|
|
001-00100
|
|
87-0233535
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
951 Yamato Road, Suite 220
Boca Raton, FL 33431
(Address of principal executive office) (zip
code)
Registrant’s telephone number, including area code: (561) 961-1900
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.001 per share
|
|
TXMD
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 8, 2021
(the “Effective Date”), TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into an Amendment
(the “Amendment”) to the Amended and Restated Employment Agreement, dated November 24, 2020, between the Company and
Mr. John C.K. Milligan, IV, the President of the Company (the “Employment Agreement”).
Pursuant to the
terms of the Amendment, as of the Effective Date, Mr. Milligan ceased to serve as the President of the Company and began to serve
as the Chief Executive Officer of vitaCare Prescription Services, Inc., a wholly-owned subsidiary of the Company. Except as otherwise
amended, the Employment Agreement remains in full force and effect and there were no changes to Mr. Milligan’s compensatory
arrangements.
The
foregoing summary of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full
text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by
reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
THERAPEUTICSMD, INC.
|
|
|
Date: April 12, 2021
|
|
|
|
|
By:
|
/s/ James C. D’Arecca
|
|
|
James C. D’Arecca
Chief Financial Officer
|
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Apr 2023 to Apr 2024